Crizotinib Versus Chemotherapy in ALK-Positive NSCLC
Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, describes a trial comparing crizotinib and chemotherapy in patients with advancedALK-positive non-small cell lung cancer.
Based on single-arm phase I and phase II trials, Shaw says, it was known that crizotinib was efficacious in this space. The primary endpoint of the trial, progression-free survival, was met.
Clinical Pearls
Crizotinib showed superiority with regard to progression-free survival compared with chemotherapy: 7.7 months versus 3.0 months. In addition, Shaw points out, crizotinib significantly increased response rates, from 20% to 65%. These data confirm the efficacy of crizotinib in this space.
- Crizotinib demonstrated superior progression-free survival compared with chemotherapy (7.7 months versus 3.0 months)
- Response rates were 65% with crizotinib versus 20% with chemotherapy
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
